23Sep/14
Picture courtesy ofIBM

IBM puts Watson to work at Johnson & Johnson and Sanofi R&D

By Ellyn McMullin, Research Associate, Axendia, Inc.

Three years after its victory on the TV quiz show Jeopardy! IBM Watson has evolved to represent a new era of computing. Today, Watson is no longer just the world’s most famous game-playing computer. IBM has put Watson to work in various industries. In healthcare, IBM is co-developing an application with Memorial Sloan-Kettering Cancer Center, and partnering with WellPoint, the University of Texas MD Anderson Cancer Center, and the Cleveland Clinic Lerner College of Medicine.
IBM announced that it is putting Watson to work in Pharma R&D at Johnson & Johnson and Sanofi. Continue reading

02Sep/14
Regulatory -Insight

What Changes Should Manufacturers Expect From FDA?

By Daniel R. Matlis

I recently had the privilege to moderate a panel entitled: “Outlook for the Medical Device Industry 2014 and Beyond: Advice from Proactive Leaders” at Camstar’s 2014 Global Conference. The panel included Vice Presidents of Operations from Advanced Bionics, ConforMIS and Terumo Cardiovascular Group.

In this, the third and final in our series of articles, we share insights and perspective from these executives addressing Regulatory issues impacting the future of the Med Tech industry. Continue reading

19Aug/14
Tech-Insight

Manufacturing Technology Insight from Proactive Leaders

By Daniel R. Matlis

I had the privilege to moderate a panel entitled: “Outlook for the Medical Device Industry 2014 and Beyond: Advice from Proactive Leaders” at Camstar’s 2014 Global Conference. The panel included Vice Presidents of Operations from Advanced Bionics, ConforMIS and Terumo Cardiovascular Group.

In this, the second in our series of articles, we share insights and perspective from these executives addressing Technology issues impacting the future of the Med Tech industry. Continue reading

11Aug/14
CFQ 2

FDA Forum Fosters Candid Discussion Between Industry and Agency

By Daniel R. Matlis

On June 26, the FDA hosted an Executive Forum on the “Case for Quality Initiative.” The forum brought together Industry Executives, FDA Officials and Industry Advisors in a series of roundtable discussions and presentations.

After the event, I had the opportunity to converse with two FDA Officials to gain their perspectives on the forum.

Continue reading